Dendreon — Merger or Acquisition (June 2003)
14 slides from Dendreon's merger presentation, Jun 10, 2003
Slide 1: Forward-Looking Statement
Forward-Looking Statement Disclaimer This presentation includes forward-looking statements, including statements about Dendreon’s proposed acquisition of Corvas, post-closing business synergies and product opportunities, and product development and commercialization. Actual results may differ materi
Slide 2: Momentum Continues in 2003
Momentum Continues in 2003 Significant Scientific Progress • Provenge ® • APC8024 • Alternative reading frames (antigen engineering) Corvas Acquisition • Stock for stock transaction • Valued at $73 M at the time of announcement, an 83% premium to Corvas’ stock price as of 2/24/03 • Value creation fo
Slide 3: Breadth in Oncology
Breadth in Oncology Vaccine Targets Antibodies Small Molecules Prodrug Program NY-ESO Trp-p8 Trp-p8 uPA CEA DN1924 Urokinase (uPA) Inhibitors Other Serine Proteases MN DN1921 (autoimmune diseases) Matriptase Inhibitors Telomerase Serine Protease Inhibitors Trp-p8 ARF DVDN CVAS
Slide 4: Advanced Clinical Trial Pipeline
Advanced Clinical Trial Pipeline Product/Target Phase 1 Phase 2 Phase 3 Provenge ® Androgen Independent Prostate Cancer Completed D9901 D9902 Androgen Dependent Prostate Cancer P-11 (Provenge alone) P-16* (Provenge+Avastin) Mylovenge ™ Multiple Myeloma rNAPc2 Acute Coronary Syndromes APC8024 Breast,
Slide 5: Provenge Induces Significant T-cell Mediated Immune Response
Provenge Induces Significant T-cell Mediated Immune Response (Week 0 to Week 8) [GRAPHIC]
Slide 6: Gleason Subgroup Change in Immune Response: Confirms MOA
Gleason £ 7 Subgroup Change in Immune Response: Confirms MOA (Week 0 to Week 8: Provenge Arm) [GRAPHIC]
Slide 7: Provenge P-16 Trial
Provenge P-16 Trial Combination Therapy with Bevacizumab (Avastin ™ ) Patient Population • Androgen dependent prostate cancer (approx. 4 times size of AIPC market) • Serologic progression after primary therapy Endpoints • Safety • Effect on PSA doubling time • Immune response
Slide 8: P-16 Trial Results to Date
P-16 Trial Results to Date PSA Doubling Time Pre-Treatment On-Treatment Median 8.2 months 21.4 months PSA Changes Decrease in PSA 3 patients (12%, 33%, 64%)
Slide 9: Provenge Collaboration Discussions
Provenge Collaboration Discussions • Discussions progressing as planned • Large market, strong data and regulatory plan have driven interest • Competitive process • Will be structured as co-development and co-promotion agreement • Global agreement minus Asia and Oceania
Slide 10: APC8024 Phase Trials
APC8024 Phase 1 Trials Patient Population • 18 patients enrolled; 16 evaluable • Advanced, metastatic breast cancer patients • Her-2 positive (2+,3+) • Failed multiple courses of chemotherapy including 15/16 who failed Herceptin • Historical median time to progression 3-6 months Endpoints • Safety •
Slide 11: APC8024 Clinical Response
APC8024 Clinical Response Clinical Benefit 25% (4/16 patients evaluated) Partial Response*: 1 patient, lasting more than 25 weeks Ongoing Stable Disease: 1 patient stable 48+ weeks 2 patients stable for more than one year No significant side effects reported, no evidence of any cardio toxicity * As
Slide 12: Key Messages: American Society of Clinical Oncology 2003 Meeting
Key Messages: American Society of Clinical Oncology 2003 Meeting • “Immunotherapy may be one of the only ways left to deal with cancer… We’ve gone as far as we can with chemotherapy.” - Dr. Herman Kattlove, American Cancer Society • Cellular therapies will be an important approach in fighting the wa
Slide 13: Preclinical Programs in Oncology
Preclinical Programs in Oncology Vaccine Targets Antibodies Small Molecules Prodrug Program NY-ESO Trp-p8 Trp-p8 uPA CEA DN1924 Urokinase (uPA) Inhibitors Other Serine Proteases MN DN1921 (autoimmune diseases) Matriptase Inhibitors Telomerase Serine Protease Inhibitors Trp-p8 ARF DVDN CVAS
Slide 14: Combining Strengths
Combining Strengths Technology Broad oncology portfolio covering 4 platforms 5 ongoing clinical programs Enhanced intellectual property estate, 87 issued U.S. patents Small molecule, medicinal chemistry expertise Operations Experienced management team Research and development expertise Collaboration